Guggenheim Issues Positive Forecast for Merck & Co., Inc. (NYSE:MRK) Stock Price

Merck & Co., Inc. (NYSE:MRK) had its price objective upped by equities researchers at Guggenheim from $146.00 to $170.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 14.18% from the stock’s previous close.

Several other research firms have also recently issued reports on MRK. Wolfe Research lifted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. Scotiabank raised their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research note on Tuesday, June 30th. Weiss Ratings upgraded Merck & Co., Inc. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 25th. Barclays lifted their price target on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Fifteen analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $149.80.

Merck & Co., Inc. Stock Down 1.0%

Shares of NYSE:MRK opened at $148.89 on Tuesday. The firm’s 50 day moving average price is $135.06 and its 200 day moving average price is $123.73. The stock has a market cap of $367.35 billion, a price-to-earnings ratio of 119.11, a price-to-earnings-growth ratio of 6.54 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $156.92. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter in the previous year, the business posted $2.13 EPS. The firm’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP David Williams sold 52,847 shares of the company’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This represents a 62.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Chirfi Guindo sold 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total value of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This represents a 24.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 over the last ninety days. Company insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of hedge funds have recently modified their holdings of MRK. Round Rock Advisors LLC raised its position in Merck & Co., Inc. by 0.7% in the 2nd quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after purchasing an additional 66 shares during the last quarter. Cascade Financial Partners LLC grew its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after purchasing an additional 80 shares during the last quarter. Somerset Trust Co grew its position in Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after purchasing an additional 81 shares during the last quarter. Stonebridge Financial Group LLC increased its stake in Merck & Co., Inc. by 0.9% in the second quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after purchasing an additional 81 shares during the period. Finally, Stronghold Wealth Management L.L.C. increased its stake in Merck & Co., Inc. by 2.6% in the second quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after purchasing an additional 82 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.